Indication
Premenstrual dysphoric disorder
Premenstrual dysphoric disorder is a severe, cyclical neuroendocrine and affective condition affecting individuals during their reproductive years. Read more about Premenstrual dysphoric disorder
144 drugs 94 manufacturers
Drugs that treat it
Common Premenstrual dysphoric disorder therapies.
FLUOXETINE HCL
SERTRALINE HCL
FLUOXETINE HCL
FLUOXETINE HCL
SERTRALINE HCL
DROSPIRENONE-ETHINYL ESTRADIOL (ethinyl estradiol/drospirenone)
SERTRALINE HCL
FLUOXETINE HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPremenstrual dysphoric disorder is a severe, cyclical neuroendocrine and affective condition affecting individuals during their reproductive years.
It is characterized by disabling psychological and somatic symptoms—predominantly marked irritability, depressed mood, affective lability, anxiety, fatigue, and physical discomfort—that emerge predictably during the late luteal phase of the menstrual cycle and resolve shortly after menses begins.
Pathophysiologically, the disorder involves an atypical central nervous system sensitivity to normal physiological fluctuations in ovarian steroids, leading to secondary dysregulation of central serotonergic signaling and GABA-A receptor modulation by neurosteroids such as allopregnanolone.
- nih.gov
Premenstrual dysphoric disorder is a severe, cyclical neuroendocrine and affective condition affecting individuals during their reproductive years It is characterized by disabling psychological and somatic symptoms—predominantly marked irritability, depressed mood, affective lability, anxiety, fatigue, and physical discomfort—that emerge predictably during the late luteal phase of the menstrual cycle and resolve shortly after menses begins Pathophysiologically, the disorder involves an atypical ...
- nih.gov
Premenstrual dysphoric disorder is a severe, cyclical neuroendocrine and affective condition affecting individuals during their reproductive years
- nih.gov
It is characterized by disabling psychological and somatic symptoms—predominantly marked irritability, depressed mood, affective lability, anxiety, fatigue, and physical discomfort—that emerge predictably during the late luteal phase of the menstrual cycle and resolve shortly after menses begins
- nih.gov
It is characterized by disabling psychological and somatic symptoms—predominantly marked irritability, depressed mood, affective lability, anxiety, fatigue, and physical discomfort—that emerge predictably during the late luteal phase of the menstrual cycle and resolve shortly after menses begins
- nih.gov
Pathophysiologically, the disorder involves an atypical central nervous system sensitivity to normal physiological fluctuations in ovarian steroids, leading to secondary dysregulation of central serotonergic signaling and GABA-A receptor modulation by neurosteroids such as allopregnanolone
- nih.gov
Pathophysiologically, the disorder involves an atypical central nervous system sensitivity to normal physiological fluctuations in ovarian steroids, leading to secondary dysregulation of central serotonergic signaling and GABA-A receptor modulation by neurosteroids such as allopregnanolone
Personalize your experience
Follow Premenstrual dysphoric disorder and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.